At least 15% of children with ADHD continue to meet full diagnostic criteria by age 25 and a further 50% meet criteria in partial remission, with European estimates of persistence up to 80%¶

Claim · All claims
Evidence · 1 study (2 entries) · review r2 · q2
Currency · newest study 2018 · not yet checked against its sources · not reviewed by a person · overdue for a recheck since 2023: baselines and conditions change

Subclaims¶

q2 i? A meta-analysis of longitudinal follow-up studies reported that at least 15% of children with ADHD meet full diagnostic criteria at age 25 and a further 50% meet criteria in partial remission with impairing subthreshold symptoms. → Franke 2018 q2 i? More recent European estimates of persistence into young adulthood for children and adolescents diagnosed with DSM-IV combined type ADHD are much higher, up to 80%. → Franke 2018 (2)

Evidence¶

Franke 2018¶

Franke, B.; Michelini, G.; Asherson, P.; Banaschewski, T.; Bilbow, A.; Buitelaar, J.K.; Cormand, B.; Faraone, S.V; Ginsberg, Y.; Haavik, J.; Kuntsi, J.; Larsson, H.; Lesch, K.P.; Ramos-Quiroga, J.A.; Réthelyi, J.M.; Ribases, M.; Reif, A. (2018). Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2018.08.001

q2 · i? · review · r2

Narrative review reporting, citing Faraone et al. (2006), a meta-analysis of longitudinal follow-up studies of children with ADHD. The review states that "at least 15% continue to meet full diagnostic criteria for ADHD by the age of 25 years" and a further 50% meet partial remission with persisting impairment. No effect size is printed.

"Meta-analysis of longitudinal follow-up studies of children with ADHD suggests that at least 15% continue to meet full diagnostic criteria for ADHD by the age of 25 years, and a further 50% meet criteria for ADHD in partial remission, with persistence of subthreshold symptoms still causing impairment"

Franke 2018 (2)¶

Franke, B.; Michelini, G.; Asherson, P.; Banaschewski, T.; Bilbow, A.; Buitelaar, J.K.; Cormand, B.; Faraone, S.V; Ginsberg, Y.; Haavik, J.; Kuntsi, J.; Larsson, H.; Lesch, K.P.; Ramos-Quiroga, J.A.; Réthelyi, J.M.; Ribases, M.; Reif, A. (2018). Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2018.08.001

q2 · i? · review · r2

The review reports, citing Cheung et al. (2015a) and van Lieshout et al. (2016b), that European estimates of persistence into young adulthood for DSM-IV combined type cases are "much higher (up to 80%)". Percentages only; no effect size printed.

"more recent estimates of persistence into young adulthood for children and adolescents diagnosed with DSM-IV combined type ADHD in Europe are much higher (up to 80%)"

Discussion¶

Related Claims¶

• A third systematic review concluded ADHD medication reduced symptoms and impairments but found limited and inconsistent evidence for long-term medication effects on social functioning, academic achievement, employment status, and psychiatric comorbidity
• A large Swedish register-based study found treatment with ADHD medication significantly reduces the risk for criminality in adults with ADHD
• ADHD is associated with poor academic outcomes, including lower grade point average, increased grade retention, and lower rates of high-school graduation and post-secondary education
• Childhood ADHD symptoms are associated with higher late-adolescent depressive symptoms in a population cohort — related